A study saw a 13% rate of serious neurological complications in hospitalized COVID-19 patients. Mortality rate was almost 40% higher than in hospitalized COVID-19 patients without neurological complications.
October 29 is World Stroke Day and stroke therapy is a core topic at the 93rd DGN Congress. Reducing stroke mortality will depend on treating more patients, faster, specially within the 'golden hour' after stroke.
Most brain changes after a COVID-19 infection are not caused by the virus, but by the body's immune response. The findings are from a study that examined 43 deceased people infected with SARS CoV-2.
Only riluzole can slow down ALS progression, and multimodal supportive therapy is the option left. A phase-II trial showed that oral administration of sodium phenylbutyrate and taurursodiol could delay progression.
A major meta-analysis confirms the advantages of catheter intervention for more severe and moderate strokes. This therapeutic option must also be made available in rural regions.
The device will be called VIKI (VIrus KIller) and can be used in schools, public offices, hospitals, dental surgeries and businesses. It aims to remove over 99.9% of bioaerosol particles.
An algorithm detects signs of osteoarthritis on an MRI scan before the first symptoms appear. With artificial intelligence, treatments could rely on drugs rather than surgery.
The latest findings in dermatological pathology - from newly discovered diseases to the background of "COVID toes" are briefly and concisely summarised.
OLLs are often triggered by medication or are a concomitant symptom of underlying inflammatory diseases, and are very similar to oral lichen planus. Differentiation and finding triggering factors is challenging.
Based on the immune cells involved in the inflammatory reaction, phenotypic differences occur. For optimal therapy, factors must be taken into account to treat the diseases’ subgroups
Chronic hand eczema (CHE) is a recurrent inflammatory reaction around the hands. Often visible, it adds a psychological burden for those affected. Delgocitinib showed a good effect with a favorable side effect profile.
Biologics have significantly improved the treatment of dermatological diseases. Their use in the treatment of melanoma and atopic dermatitis was discussed during the virtual EADV Congress on 31 October 2020.
The study highlights how SARS-COV-2 manifests itself through respiratory or mental symptoms, and also through very specific neuropsychological signs such as agraphia and conduction aphasia.
Infections with SARS-CoV2 also manifest themselves on the skin. Different patterns of dermatological symptoms were presented and the underlying pathophysiology discussed at the virtual EADV Congress 2020.
BRAF and MEK inhibitors have been proving their worth for years in melanoma treatment. A number of substances are in clinical development and testing for psoriasis and other inflammatory diseases.
Prof. Stratigos covers the virtual congress' hot topics, such as microbial therapy for psoriasis, the influence of artificial intelligence, and the challenges of the COVID-19 pandemic.
An open-label study from France showed that a low-FODMAPs diet did not have any benefit over a standard diet to improve symptoms in patients with PPI-refractory gastro-oesophageal reflux disease (GERD).
A prospective population-based study from Sweden demonstrated for the first time a possible causal link between duodenal inflammation and psychological distress in a functional gut disorder.
The appearance of Bifidobacterium longum NCC2705 in duodenal aspirates was associated with a concomitant increase in serpin concentration in celiac disease or non-celiac gluten-sensitivity patients.
Most IBS patients who responded to fecal transplantation maintained this response after 1 year. Improvements in symptoms, quality of life, fecal bacterial profile, and short-chain fatty acids increased significantly.